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Knowledge on the influence of developmental changes on 
drug pharmacokinetics (PK) and pharmacodynamics is lim-
ited. This may cause the high off-label and unlicensed drug 
prescription observed in the pediatric population,1 as well as 
complicate the selection of first-in-child doses during drug 
development. As it would require a tremendous amount of 
resources to thoroughly investigate changes in drug PK 
and pharmacodynamics throughout the entire pediatric age 
range for each individual drug, new approaches to expedite 
the development of safe and effective pediatric dosing regi-
mens and first-in-child doses are necessary.
To apply modeling approaches throughout the entire pedi-
atric population, reliable and precise qualitative and quantita-
tive information on developmental changes in various parts of 
the physiological system that are involved in all the underlying 
absorption, distribution, metabolism, and elimination processes 
are required. It is imperative to develop maturation functions 
that quantify developmental changes in metabolic and elimina-
tion pathways, because drug clearance drives drug exposure, 
and differences in drug exposure are thought to be the major 
cause of age-dependent differences in pediatric drug dose 
requirements.2 For metabolic pathways, quantitative informa-
tion on enzyme activity can be obtained from in vitro studies; 
however, for instance, for uridine 5′-diphosphate glucuronisyl-
transferase-mediated glucuronidation, this type of information 
is limited for the pediatric population.3 We therefore investigated 
whether maturation functions for metabolic pathways can be 
obtained from pediatric population PK covariate models that 
are based on in vivo outcome measures. Population modeling 
allows for the simultaneous analysis of sparse, dense, and/
or unbalanced data, which may even have been collected for 
clinical purposes (e.g., therapeutic drug monitoring). In fact, by 
combining historic data from multiple sources, the burden to 
individual patients can be significantly reduced, while improv-
ing the precision of the parameter estimates in a resulting 
population model. In population models, the net influence of 
developmental changes in underlying physiological processes 
on drug clearance is quantified in covariate models.
In this proof-of-concept study, we test the hypothesis that 
pediatric population PK covariate models contain quantitative 
information on the influence of maturational changes in the bio-
logical system on drug PK and that these covariate models can 
therefore be extrapolated between drugs that share elimination 
pathways.4 For this study, an internally and externally validated 
pediatric covariate relationship for morphine glucuronidation in 
patients younger than 3 years was directly incorporated into 
a population model for zidovudine glucuronidation in patients 
younger than 5 months. As both drugs are primarily elimi-
nated through the UDP-glucuronosyltransferase 2B7-mediated 
glucuronidation,5–7 this model was called the system-specific 
model. The performance of this model was compared with the 
performance of a reference model that was based on a com-
prehensive covariate analysis of the zidovudine data alone.
Results
Patients and data
The current analysis is based on 473 zidovudine concen-
trations and 173 zidovudine-glucuronide concentrations 
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collected on 68 occasions from 29 individuals varying from 
term neonates to infants up to 5 months of age (PACTG 
049).8 For each patient, dense data were available from multi-
ple occasions that were days or weeks apart. Zidovudine was 
administered both intravenously and orally to each patient. 
Data were obtained after single-dose administrations on 
separate occasions and for eight patients, data from admin-
istrations that were part of a long-term oral dosing regimen 
were available as well. This data set was used to develop the 
two population models in this study. An example of the data 
records for two patients at the extremes of the age range is 
provided in the supplementary Data online.
A data set of morphine and its glucuronides in 248 preterm 
and term neonates to 3-year-old infants was used to obtain 
the pediatric covariate model used in the system-specific 
model.9 In table 1, study and patient characteristics for the 
zidovudine data set used for both models in this analysis and 
the morphine data sets used to obtain the pediatric covariate 
model are shown for comparison.
system-specific and reference model for zidovudine
Figure 1 shows the structural model for zidovudine, which is 
the same for both the system-specific model and the refer-
ence model, and the covariate equations, which are different 
between the two models.
For the structural model, a two-compartment model 
(V1 and V2) was found to describe the bimodal decline in 
zidovudine concentrations in time. Both distribution volumes 
were set to be equal. A one-compartment model was used 
to describe the time course of the zidovudine-glucuronide 
(V3) with the distribution volume estimated as a fraction of 
the central compartment (θv3). Zidovudine absorption was 
described by first-order absorption (k
a
) and the oral bioavail-
ability (F) was estimated.
For the error model, significant interindividual variability 
could be identified in both models for the absorption rate 
constant (k
a
), the formation (Cl1) and elimination (Cl2) clear-
ance of zidovudine-glucuronide, the distribution volume of 
the central compartment (V1), and the bioavailability (F). The 
interindividual variability and residual error for both models 
were best described by a proportional error model.
The covariate model was different for the system-specific 
model and the reference model (Figure 1).
System-specific model. A previously published covariate 
model for glucuronidation of morphine in patients varying 
from preterm neonates to children of 3 years9,10 was directly 
incorporated in the model for zidovudine. This covariate 
model consisted of a body weight-based exponential equa-
tion with an exponent of 1.44 for the formation and elimina-
tion of zidovudine-glucuronide, with a reduced formation 
clearance of zidovudine-glucuronide in neonates within 10 
days of birth, and linear relationships between body weight 
and distribution volumes.9
Reference model. A comprehensive covariate analysis iden-
tified age (either postnatal or postmenstrual age) and body 
weight as predictive and statistically significant covariates for 
the formation (Cl1) and elimination (Cl2) clearance of zidovu-
dine-glucuronide. Due to the relatively small range in body 
weight and age of the patients in the current zidovudine data set 
(table 1), only small differences in objective function and diag-
nostics between models using either of the three covariates or 
between models using these covariates in different equations 
(i.e., linear, exponential, or sigmoidal) were obtained. On the 
basis of objective function, postnatal age was found to be a 
slightly superior covariate for both Cl1 and Cl2. The inclusion of 
this covariate was most optimal in a sigmoidal relationship on 
Cl1 and in a linear relationship with estimated y-intercept on Cl2. 
No other statistically significant covariates were identified.
In table 2, the model parameter estimates obtained for the 
system-specific and reference models are provided, showing 
similar values for the structural parameters and the param-
eters of the error model. The table also shows that for both 
models the coefficients of variation of the fixed effects remain 
well below 50%, indicating that the parameters can be esti-
mated with acceptable precision. The coefficients of variation 
of some of the variance estimates of the interindividual vari-
ability did exceed 50%, indicating that the information in the 
data set was uninformative for precise estimation of these 
parameter values. The NONMEM code for two final models is 
provided in the supplementary Data online.
Figure 2 shows population-predicted zidovudine clearances 
(Cl1) for the reference model vs. the system-specific model. As 
data were available on different occasions that were days or 
weeks apart, the covariates (body weight and postnatal age) 
differed for each child on the different occasions, yielding dif-
ferent clearance predictions per child per occasion. The figure 
shows that both models estimate similar population clearance 
values for each individual at each occasion, despite the differ-
ences in covariate model as depicted in Figure 1.
table 1 Patient and study characteristics of the zidovudine data set that 
was analyzed in this study to build the system-specific model and the 
reference model, and of the morphine data set that was used to build the 
pediatric covariate model applied in the system-specific model
characteristic Zidovudine data set8 Morphine data set9
Number of patients 29 248
Number of samples of 
parent compound
473 792
Number of samples of 
glucuronide
173 (G-ZDV) 664 (M3G); 722 (M6G)
Administration route Oral and bolus i.v. Short term and  
continuous i.v.
Duration Multiple occasions 
days or weeks apart
Single occasion of up to 
5 days
Sampling Dense Sparse
Population Healthy patients Ventilated and  
postoperative  
(noncardiac surgery) 
patients
Postnatal age  
(median (range), days)
21 (2–145) 33 (0–1,071)
Postmenstrual age 
(median (range), 
weeks)
43 (36–57) 42 (25–193)
Body weight  
(median (range), kg)
3.8 (1.9–6) 3.6 (0.5–16.8)
Sex (M/F) 18/11 (62%/38%) 144/104 (58%/42%)
G-ZDV, zidovudine-glucuronide; M3G, morphine-3-glucuronide; M6G, 
morphine-6-glucuronide.
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Structural model
Oral depot
(ZDV)
Dose × F
ka
Qeq
Cl1
Cl2
V1
(ZDV)
V3
(G-ZVD)
V2
(ZDV)
Covariate models
System-specific model
V1 = V2 = θV1 × BW
V3 = V2 × θV3
Cl1 PNA < 10 days = θCl1 < 10 days × BW
1.44
Cl1 = 
θCl1 max  × (PNA/PNAmedian)
Cl2 = θCl2 sl  × (PNA/PNAmedian) + θCl2 int
θPNA 50  + (PNA/PNAmedian)Cl1 PNA > 10 days = θCl1 < 10 days × BW1.44
Cl2 = θCl2 × BW
1.44
V1 = V2
V3 = V2 × θV3
Reference model
Figure 1 Schematic representation of the structural model for the zidovudine models (left) and equations of the covariate relationships 
in the reference model (middle) and the system-specific model (right). BW, body weight; Cl, clearance of designated route; F, bioavailabil-
ity; G-ZDV, zidovudine-glucuronide; k
a
, absorption rate constant; PNA, postnatal age with subscript “median” indicating the median value 
of the individuals at the different occasions; Q
eq intercompartmental clearance; V, distribution volume of designated compartment; ZDV, 
 zidovudine; θV, distribution volume of designated compartment as fraction of V1; θCl1max, maximum value of the zidovudine glucuronidation 
clearance; θPNA 50, postnatal age at which half the maximum value of zidovudine glucuronidation clearance is reached; θCl sl2 , slope of the line 
describing age-related changes in zidovudine-glucuronide elimination clearance; θCl int2 , y-intercept of the line describing age-related chang-
es in zidovudine-glucuronide elimination clearance; θCl days1 10> , population value of zidovudine glucuronidation clearance value in  children 
within 10 days of birth; θCl days1 10> , population value of zidovudine glucuronidation clearance value in children older than 10 days; θCl2, population 
value of zidovudine-glucuronide elimination clearance value.
table 2 Final parameter estimates of the system-specific model and the reference model for zidovudine glucuronidation
Pharmacokinetic  
parameter (unit)
system-specific model Reference model
Model parameter (unit) Value (cV%) Model parameter (unit) Value (cV%)
Fixed effects
F θ 1.55 (30.6) θ 1.56 (21.0)
F (%) 82.5 F (%) 82.6
k
a
 (min−1) 0.031 (17.7) 0.0307 (0.9)
V1 = V2 (l/kg) 1.08 (11.4) (l) 4.02 (1.3)
V3 (fraction of V1) 0.211 (18.3) 0.226 (20.4)
Cl1 Cl1<10days (l/min/kg1.44) 0.00435 (12.1) Cl1 max (l/min) 0.116 (7.6)
Cl1>10days (l/min/kg1.44) 0.00853 (11.7) ClPNA 50 (days) 1.63 (17.9)
Cl2 Cl2 (l/min/kg1.44) 0.00231 (10.7) Cl2 sl (l/min/day) 0.00257 (17.5)
Cl2 int (l/min) 0.00911 (11.64)
Q
eq (l/min) 0.0289 (11.7) 0.0275 (11.8)
Interindividual variability
ω2 (F) 2.82 (45.0) 2.78 (42.5)
ω2 (k
a
) 0.607 (39.9) 0.625 (36.8)
ω2 (V1) 0.366 (49.7) 0.443 (56.2)
ω2 (Cl1) 0.255 (54.51) 0.328 (38.7)
ω2 (Cl2) 0.112 (70.3) 0.142 (46.3)
ω2 (V1–Cl1) interaction — 0.312 (54.5)
Residual error
σ 2 (ZDV) 0.11 (11.5) 0.11 (7.2)
σ 2 (G-ZDV) 0.158 (15.5) 0.152 (13.3)
Cl, clearance of designated route; CV, coefficient of variation; G-ZDV, zidovudine-glucuronide; k
a
, absorption rate constant; Q
eq, intercompartmental  clearance; 
V, distribution volume of designated compartment; ZDV, zidovudine; F, bioavailability presented as value of θ in Eq. 2 and population value of F calculated with 
Eq. 2; ω2, variance of the normal distribution that quantifies the interindividual variability on the designated parameter according to Eq. 1 or Eq. 2 for bioavailability; 
σ 2, variance of the normal distribution that quantifies the residual error of the designated observation according to Eq. 3.
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Model evaluation
The reference model was statistically superior over the 
system-specific model in describing the zidovudine data, as 
demonstrated by a difference in objective function value of 13 
points at a 2-point difference in degrees of freedom.  Figure 
3 shows the goodness-of-fit graphs that are stratified by age 
into one group that is older than and another group that is 
younger than 38 days (the median age of the individuals at 
the different occasions). Visual inspection of these graphs 
shows that both models can describe the observed zidovu-
dine concentrations in children older and younger than the 
median age without bias and that the difference between the 
plots of the two models is negligible.
The plots in Figure 4 show that the covariate relationships 
for zidovudine clearance (Cl1) of both the system-specific and 
reference model describe individual glucuronidation clear-
ances without bias, despite the use of different covariates 
(i.e., body weight for the system-specific model and postna-
tal age for the reference model). Accuracy of the individual 
zidovudine clearance values compared with the population 
values described by the covariate relationships was numeri-
cally quantified as mean percentage error and was 20.5% 
for the reference model and 11.3% for the system-specific 
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Figure 3 Basic goodness-of-fit plots for zidovudine of the system-specific model (top) and the reference model (bottom). On the left are 
population-predicted concentrations vs. observed concentrations, in the middle are conditional weighted residuals (CWRES) vs. time 
after last dose, and on the right are CWRES vs. population-predicted concentrations. The plots are stratified by age, with solid circles 
indicating observations in children on occasions that they were younger than 38 days, the median age of the individuals at the different 
occasions, and open circles indicating observations in children on occasions that they were older than 38 days.
Figure 2 Population-predicted zidovudine clearances (Cl1) for the 
reference model vs. the system-specific model for each individual 
at each separate study occasion.
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model. The precision, numerically quantified as root mean 
square error, was 19.2% for both models.
In terms of predictive performance, the two models perform 
similar as well, as expressed by the results of the normal-
ized prediction distribution error (NPDE) analysis shown in 
Figure 5. This figure shows that the system-specific model 
and the reference model can accurately predict the median 
zidovudine concentrations, but they slightly overestimate the 
variability in the observations. In addition, there is no bias in 
NPDEs in time or across the concentration range for any of 
the models.
DiscussiOn
Our group previously described and defined a distinction 
between drug-specific and system-specific parameters in 
population models.11 This investigation is a proof-of-concept 
study to examine whether the context of system-specific prop-
erties can be extended to include not only static descriptors 
of the physiological system but also temporal changes in the 
physiological system as a result of developmental changes in 
the pediatric population. It was shown that a covariate model 
for the glucuronidation of morphine in preterm and term neo-
nates to children up to the age of 3 years9,10 also accurately 
reflects developmental changes in zidovudine glucuronida-
tion clearance in term neonates and infants. Similar results 
have been obtained by our group for the glomerular filtra-
tion of antibiotics in neonates.12 These results support the 
hypothesis that pediatric covariate models for drug clearance 
may serve as semiphysiological functions in population PK 
 models, although further research should reveal the general-
izability of this approach in scenarios with different drug and 
patient characteristics.
For the maturation of metabolic pathways, functions 
obtained with population modeling from in vivo sources reflect 
the net effect of maturational changes in multiple underlying 
physiological systems. This may include changes in expres-
sion and function of drug metabolizing enzymes and active 
transporters, changes in cardiac output and organ perfusion, 
changes in acid–base balance, and changes in the amount 
and composition of drug-binding plasma proteins and other 
blood components that may influence plasma protein bind-
ing.13 Unfortunately, quantitative knowledge on all these 
underlying processes is incomplete especially for the pedi-
atric population, impeding the use of pediatric physiologically 
based PK (PBPK) models. In addition, data on enzyme activ-
ity obtained from in vitro data may not accurately reflect the in 
vivo situation, especially for uridine 5′-diphosphate glucuroni-
syltransferase enzymes.3,14,15 Combining information from 
population PK models with PBPK approaches may therefore 
be necessary to obtain functions to describe the maturational 
changes in metabolic and/or elimination pathways. These 
modeling approaches are crucial for determining evidence-
based pediatric dosing algorithms and first-in-child doses.
The proposed semiphysiological modeling approach can 
be performed using data routinely obtained in pediatric phar-
macokinetic trials. In fact, this approach allows for the use of 
denser information or information from a wider age range than 
may be available for the analysis of the unstudied drug. This 
is especially important in the pediatric population where often 
only limited data are available for ethical and practical reasons. 
The system-specific model of this analysis was, for instance, 
based on data from 248 patients ranging from preterm neo-
nates to infants of 3 years, whereas in the current zidovudine 
analysis, data from only 29 patients ranging from term neo-
nates to infants of 5 months were available (table 1). The small 
range in age and body weight of the patients in the zidovudine 
data set made it difficult to discriminate model performance 
between submodels. The covariate relationship identified for 
morphine glucuronidation was probably not identified as most 
significant in the comprehensive covariate analysis of the cur-
rent zidovudine data due to the indistinctive curvature of this 
relationship in the body weight range of the zidovudine data 
set. Nonetheless, in the system-specific model, direct incorpo-
ration of the pediatric covariate model obtained with morphine 
did provide a good description of the population and individual 
zidovudine clearance parameters as shown in Figure 4. In 
this approach, it is, however, a prerequisite that the covariate 
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models are validated both internally and externally and that 
the population to which the covariate model applies is well 
defined in terms of other potentially important covariates, like, 
for instance, genetics or disease status. In case covariates 
other than size and/or age are identified in a pediatric cova-
riate model, we envision that the complete covariate model 
describes the biological system and that therefore this com-
plete covariate model should be extrapolated between drugs.
In contrast to PBPK models, a drawback of population PK 
modeling is that the analysis has to be repeated for each indi-
vidual drug for each pediatric age group. This study suggests 
that the between-drug extrapolation of semiphysiological 
pediatric covariate functions can be used to develop pediatric 
population PK models of hitherto unstudied drugs in a more 
time-efficient manner. However, the use of the semiphysi-
ological glucuronidation function in the population analysis of 
zidovudine still relied on the availability of at least a limited 
amount of pediatric data to determine the population value of 
the clearance, which is mainly determined by the drug-spe-
cific parameters K
m
 and V
max
. This does not pose a problem 
for marketed drugs that are already being used off-label in a 
population, but when in drug development a drug has never 
been used in a pediatric age range before, a methodology that 
does not rely on in vivo pediatric data of the drug under inves-
tigation is required. To date, there is no suitable methodology 
based on population PK modeling available to extrapolate 
pediatric PK parameters from older to younger age ranges 
in the drug development process.16 If system-specific profiles 
on developmental changes in specific metabolic pathways 
were, however, available over the entire pediatric age range, 
these profiles could be used in a semiphysiological modeling 
approach to design successive studies in children of decreas-
ing ages for unstudied drugs. These studies could then be of 
a confirmative rather than an explorative nature.
Concerning the net observed maturational changes in 
drug clearance in this study, it is emphasized that the weight 
that each change in the physiological system has may be 
different for drugs with different physicochemical and PK 
 properties. Morphine and zidovudine are quite similar with 
respect  to these properties. Their molecular masses are 285 
and 267 g/mol, respectively. The acid dissociation constant 
(pK
a
) values for morphine are 7.9 and 9.617 and for zidovudine 
this value is around 9.718,19 and the octanol/water partition coef-
ficient (log P) values for these compounds were reported to be 
around 0.7517 and 0.05,20,21 respectively. Plasma protein bind-
ing in adults ranges between 23 and 38% for both drugs,20,22,23 
and their hepatic extraction ratios in adults range between 
0.5 and 0.65.24–26 We cannot exclude that these similarities in 
drug characteristics have contributed to the good extrapolation 
potential of the pediatric covariate model for glucuronidation 
observed in this study, therefore, further studies on the appli-
cability of the semiphysiological function for glucuronidation in 
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children are required. For this, in silico studies using a PBPK 
modeling approach could be performed to reveal whether, how, 
and to what extent differences in physicochemical drug proper-
ties influence the between-drug extrapolation potential of the 
semiphysiological glucuronidation function. This can be done 
by simulating in vivo pediatric drug clearance of hypothetical 
drugs with various physicochemical drug properties that are all 
eliminated through the same pathway (see Part II of this article, 
ref. 27). Investigation of maturation patterns in individual physio-
logical parameters and PBPK simulations of scenarios in which 
values of these parameters are altered may reveal whether the 
changes in drug clearance quantified by a pediatric semiphysi-
ological function mainly result from changes in a single or mul-
tiple parameters (see Part II of this article, ref. 27). This can be 
used to determine whether a population covariate relationship 
can be directly incorporated in PBPK models or whether further 
deconvolution of the covariate relationship is necessary. The 
advantage of PBPK model in drug development would be that 
it may aid in determining the absolute value of drug clearance 
without prior pediatric in vivo data.
In conclusion, this proof-of-concept study supports our hypoth-
esis that pediatric population covariate models that describe the 
developmental changes in drug elimination pathways consti-
tute system-specific rather than drug-specific information. This 
system-specific information can be used in a semiphysiological 
manner in the development of pediatric population PK models 
of drugs that share clearance pathways. Further analysis of the 
physicochemical and physiological basis of the pediatric semi-
physiological glucuronidation function should reveal whether 
this function can be directly incorporated in PBPK models for all 
substrates or whether it is necessary to separate the covariate 
relationship further into components to describe the influence 
of the various physiological changes.
MetHODs
Study design. Two population PK models were developed for 
a single data set of zidovudine and its glucuronide.
System-specific model: In this model, a covariate model for 
morphine glucuronidation in patients younger than 3 years 
that was validated both internally and externally using vari-
ous tools9,10 was directly incorporated.
Reference model: For this model, a comprehensive covariate 
analysis was performed yielding a PK model with a set of 
covariate relationships that best described the current zido-
vudine data according to predefined statistical criteria.
The performance of both models was evaluated according to 
a previously published framework for the validation of pedi-
atric population models,28 and the results of this evaluation 
for the system-specific model (A) were compared with the 
results obtained for the reference model (B).
Patients and data. Data were obtained from a multicenter 
study to evaluate the safety, tolerability, and PK of zidovudine 
as a prophylaxis to prevent mother-to-child HIV transmission in 
healthy neonates and infants born to HIV-infected women. The 
study protocol was approved by institutional review boards of 
the participating institutions and written informed consent was 
obtained from the parents or legal guardians of each patient.
Model development. NONMEM VI (ICON, Ellicott City, MD) 
was used to perform the data analysis, with PLT Tools version 
3.0.0.29 in combination with R version 2.10.0 for the visualiza-
tion of the data. All parameter estimates were obtained with 
the first-order conditional estimation method with interaction.
Model development for the reference model and the system-
specific model was performed in three steps: choice of struc-
tural model; choice of error model; and choice of the covariate 
model.
For both models, the first two steps in the model devel-
opment process (i.e., the choice of the structural and error 
model) were the same. One- and two-compartment models 
were tested for the structural model. For the error model, 
interindividual variability on the model parameters was tested 
assuming a log-normal distribution described by an exponen-
tial distribution model depicted in Eq. 1. For bioavailability (F), 
interindividual variability was described using Eq. 2 to avoid 
individual bioavailability estimates of more than 100%
(1)
(2)
In these equations, Pi is the individual parameter estimate 
for the i th individual, θ represents the population parameter 
estimate for parameter P, and ηi is a random variable for the 
i th individual from a normal distribution with a mean of zero 
and estimated variance of ω 2. For the intraindividual variabil-
ity and residual error in the observed zidovudine and zidovu-
dine-glucuronide concentrations, proportional, additive, and 
combination error models were tested.
The likelihood ratio (assumed to be χ2 distributed) was used 
to assess whether the difference between (sub)models was 
statistically significant. A decrease in the objective function 
corresponding to P < 0.01 was considered to be significant. In 
addition, the following basic goodness-of-fit plots were used 
for diagnostic purposes (i) observed vs. individually predicted 
concentrations, (ii) observed vs. population- predicted con-
centrations, (iii) conditional weighted residuals vs. time, and 
(iv) conditional weighted residuals vs. population-predicted 
concentrations. Furthermore, the 95% confidence intervals 
of the model parameters and the correlation matrix were 
assessed.
The third and final step of the model development process 
(i.e., choice of the covariate model) was different for the refer-
ence model and the system-specific model:
System-specific model: The previously obtained and vali-
dated covariate model for morphine glucuronidation in chil-
dren within 3 years9,10 was directly incorporated into the 
model for zidovudine. Specifically, a body weight-based 
exponential equation with an exponent of 1.44 for the forma-
tion and elimination of zidovudine-glucuronide with a reduced 
formation clearance of zidovudine-glucuronide in neonates 
within 10 days of birth was included, as was a linear cor-
relation for distribution volume of the parent compound and 
metabolite. Although this pediatric covariate model describes 
the rate of developmental changes in clearance and distribu-
tion volume, the population values of these parameters for 
zidovudine were estimated by NONMEM.
Pi i= ×θ ηexp( )
Pi = +
e
e
θ η
θ η
+
+1
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Reference model: A comprehensive covariate analysis with 
forward inclusion and backward deletion of covariates was 
performed to obtain a covariate model with the best description 
of the current zidovudine data according to statistical criteria. 
The following covariates were tested for significance: post-
natal age, postmenstrual age, gestational age at birth, body 
weight, sex, and creatinine clearance. The continuous cova-
riates were tested in linear equations, exponential equations 
with estimated exponents, or sigmoidal equations. A decrease 
in the objective function corresponding to P < 0.01 for the for-
ward inclusion of covariates was considered to be significant. 
In addition, the aforementioned diagnostic criteria were used. 
When more than one significant covariate was identified, the 
most significant covariate was included in the model and the 
resulting model served as the basis for the subsequent explo-
ration of additional covariate effects. For the backward deletion 
of covariates, an increase in objective function corresponding 
to P < 0.001 was considered to be significant.
Model evaluation. Although the system-specific and reference 
models are not nested, they are based on the same patients 
and data, and therefore, the −2 log likelihood, by means of 
the NONMEM objective function, was used to statistically 
compare the description of the zidovudine data by the system-
 specific model with the description of the zidovudine data by 
the reference model. To directly compare clearance predictions 
between the two models, population clearance predictions from 
the reference model were plotted vs. population clearance pre-
dictions from the system-specific model. For each patient, data 
were obtained at multiple occasions, as age and bodyweight 
change rapidly in this young population one population predic-
tion was obtained per patient per occasion.
According to the framework for the validation of pediatric 
population models,28 the basic goodness-of-fit plots of the 
models were inspected. These plots were stratified by age 
into a group that was younger and a group that was older 
than 38 days (the median age of the individuals at the dif-
ferent occasions) to ascertain that the entire age range was 
described equally well. In addition, the covariate relationships 
describing the population-predicted zidovudine clearance 
(Cl1) and the individual post hoc clearance estimates of each 
individual at each separate study occasion were plotted in 
one graph for each model to visually assess the description of 
the individual zidovudine glucuronidation clearances (Cl1) by 
the covariate relationships. Finally, bias and precision of the 
individual zidovudine glucuronidation clearance values com-
pared with the population-predicted clearances described by 
the covariate relationships were quantified by calculating the 
percentage mean prediction error (%MPE, Eq. 3) and the 
root mean square error (RMSE, Eq. 4), respectively.
(3)
(4)
To compare the predictive properties of both models, an 
NPDE analysis,30 which is a simulation-based diagnostic, 
was used. The entire data set was simulated 1,000 times in 
NONMEM and subsequently each observed concentration 
was compared with the reference distribution of the simu-
lated data points using the NPDE add-on package in R.31
acknowledgments. This study was performed within the framework 
of Top Institute Pharma project number D2-104. The work of C.A.J.K. is 
supported by the Innovational Research Incentives Scheme (Veni grant, 
July 2006) of the Dutch Organization for Scientific Research (NWO). 
Overall support for the International Maternal Pediatric Adolescent AIDS 
Clinical Trials Group (IMPAACT) was provided by the National Institute 
of Allergy and Infectious Diseases (NIAID) (U01 AI068632), the Eunice 
Kennedy Shriver National Institute of Child Health and Human Develop-
ment (NICHD), and the National Institute of Mental Health (AI068632). 
The content is solely the responsibility of the authors and does not nec-
essarily represent the official views of the National Institutes of Health. 
This work was supported by the Statistical and Data Analysis Center at 
Harvard School of Public Health, under the NIAID cooperative agree-
ment no. 5 U01 AI41110 with the Pediatric AIDS Clinical Trials Group 
(PACTG) and no. 1 U01 AI068616 with the IMPAACT Group. Support of 
the sites was provided by the NIAID and the NICHD International and 
Domestic Pediatric and Maternal HIV Clinical Trials Network funded by 
NICHD (contract number N01-DK-9-001/HHSN267200800001C). We 
thank Gregory Sivolapenko from the Laboratory of Pharmacokinetics 
of the University of Patras for his support.
author contributions. E.H.J.K., M.N., D.T., E.C., M.M., and C.A.J.K. 
designed the research. M.N., E.C., and M.M. performed the research. 
E.H.J.K., E.P., M.D., and C.A.J.K. analyzed the research. E.H.J.K., 
M.N., E.P., D.T., E.C., M.D., M.M., and C.A.J.K. wrote the manuscript.
conflict of interest. All authors declared no conflict of interest.
%MPE
(populationCl individualCl)
individualCl 100=
−
×
∑
n
RMSE
(populationCl individualCl)2
=
−∑
n
study Highlights
WHat is tHe cuRRent KnOWleDge On  
tHe tOPic?
Drug clearance differs between adults and children and 
between children of different ages, which is believed to be 
the major cause of age-dependent differences in pediatric 
drug dosing requirements.
WHat QuestiOn DiD tHis stuDY aDDRess?
To improve the availability of maturation functions for 
specific elimination pathways that can be used for mod-
eling and simulation, this study tests whether biological 
system-specific information can be obtained from pediat-
ric population PK covariate models.
WHat tHis stuDY aDDs tO OuR KnOWleDge
Using two drugs with similar physicochemical properties 
in a pediatric population younger than 3 years, this proof-
of-principle study supports the hypothesis that pediatric 
population covariate models for drug clearance contain 
biological system-specific information and can be extrap-
olated between drugs that share elimination pathways in 
a semiphysiological modeling approach.
HOW tHis MigHt cHange clinical 
PHaRMacOlOgY anD tHeRaPeutics
A semiphysiological modeling approach will expedite the 
development of pediatric population models and physi-
ologically based models that are crucial for the develop-
ment of evidence-based and first-in-child dosing regimen.
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